Basal cell nevus syndrome drug market was valued at $9.50 million in 2025 and is projected to reach $19.05 million by 2035, registering a CAGR of 7.3% during the forecast period from 2026 to 2035. The global basal cell nevus syndrome drug market is witnessing renewed momentum as biotechnology companies intensify clinical development and patient-focused collaborations. In October 2025, Medicus Pharma Ltd. announced a strategic collaboration with the Gorlin Syndrome Alliance to provide compassionate access to SKINJECT™, its investigational doxorubicin-containing microneedle array designed for patients with Gorlin Syndrome. This initiative reflects a growing emphasis on expanding treatment access for individuals affected by nevoid basal cell carcinoma syndrome and reinforces the shift toward targeted therapeutic approaches within this rare disease segment.
Browse the full report description of “Basal Cell Nevus Syndrome Drug Market Size, Share & Trends Analysis Report by Type (Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, and Others), and by Application (Hospital, Clinics / Outpatient Centers, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/basal-cell-nevus-syndrome-drug-market
In August 2024, Inhibitor Therapeutics advanced its itraconazole formulation specifically for treating basal cell carcinomas in Gorlin Syndrome patients. The company partnered with The Gorlin Syndrome Alliance and engaged its Scientific Advisory Board to support regulatory advancement and facilitate discussions with the US Food and Drug Administration. During the same period, DermBiont reported positive initial Phase 2a data for SM-020, a topical kinase inhibitor under development for locally advanced basal cell carcinoma and for prevention of basal cell carcinoma in Gorlin Syndrome patients. The ongoing open-label study evaluates tumor size reduction at week six and monitors safety outcomes, supporting continued clinical progression in this niche therapeutic space.
Earlier strategic developments further strengthened the competitive landscape. In November 2023, Sol-Gel Technologies initiated Phase 3 trials for SGT-610 (patidegib gel, 2%), a topical hedgehog inhibitor intended to prevent new basal cell carcinoma lesions in Gorlin Syndrome patients. The therapy, acquired from PellePharm in January 2023, represents a targeted approach for a rare condition that currently lacks US Food and Drug Administration or European Medicines Agency approved treatments. Collectively, these developments signal a structured shift toward topical, pathway-specific, and patient-centric therapies, reinforcing innovation and expanding the clinical pipeline within the global basal cell nevus syndrome drug market.
Market Coverage
Key questions addressed by the report.
Global Basal Cell Nevus Syndrome Drug Market Report Segment
By Type
By Application
Global Basal Cell Nevus Syndrome Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/basal-cell-nevus-syndrome-drug-market